Anti CD19 CAR NK cells therapy(Shahid Beheshti University Of Medical Sciences)

N/A

Report date: 2024/10/12 20:00:06

Base Information

Drug NameAnti CD19 CAR NK cells therapy(Shahid Beheshti University Of Medical Sciences)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy

Mechanisms of ActionNatural killer cell replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryIran

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesShahid Beheshti University Of Medical Sciences

China Registration ClassN/A

Develop Information

Active CompaniesShahid Beheshti University Of Medical Sciences

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A